Oritavancin diphosphate

ALTERNATE NAME: (4"R)-22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-α-L-arabino-hexopyranosyl)-N3"-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-vancomycin, diphosphate
LY 333328
LY-333328

CATALOG #:

B2713-5	5 mg
B2713-25	25 mg

STRUCTURE:



MOLECULAR FORMULA: $C_{86}H_{97}Cl_3N_{10}O_{26} \cdot 2H_3PO_4$

MOLECULAR WEIGHT: 1989.09

CAS NUMBER: 192564-14-0

APPEARANCE: White to off-white solid

PURITY: ≥98% by HPLC

SOLUBILITY: ~10 mg/ml Water

DESCRIPTION: Oritavancin diphosphate is a second-generation, semi-synthetic lipoglycopeptide, that is derived from chloroeremomycin, an analogue of vancomycin. Similar to vancomycin, it contains a core heptapeptide; however, its unique lipophilic side chain provides oritavancin with a prolonged half-life compared to the parent drug. Oritavancin has a multifaceted mechanism of action that displays concentration-dependent effects against gram-positive organisms. Similar to vancomcyin and other glycopeptides, oritavancin inhibits cell wall biosynthesis by binding noncovalently to the D-alanyl-D-alanine terminal ends of the peptidoglycan chain and pentaglycine bridge, thereby inhibiting transglycosylation and transpeptidation.

STORAGE TEMPERATURE: -20ºC. Protect from moisture

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

RELATED PRODUCTS:

Dirithromycin (B2693)
Vancomycin Hydrochloride (B1507)

DISCLAIMER: ***FOR RESEARCH USE ONLY! Not to be used on humans.***